Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Drug composite and application thereof

A composition and medicine technology, applied in the field of medicine, can solve the problems such as difficulty in exerting the slow-release effect of hyaluronic acid, unfavorable environmental protection, high viscosity of hyaluronic acid, etc.

Inactive Publication Date: 2011-02-02
INST OF BIOPHARM OF SHANDONG PROVINCE
View PDF17 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the combined drug needs to change the syringe during injection, which is cumbersome to operate, increases the chance of pollution, and wastes drug packaging, which is not conducive to environmental protection; more importantly, the two drugs are injected one after another. Due to the high viscosity of hyaluronic acid, the drug is not easy to disperse evenly in hyaluronic acid. In the mesh gel, it is difficult to exert the sustained release effect of hyaluronic acid only by simple mixing, and the drug is quickly dispersed and lost, and the therapeutic effect is reduced. When injected into the eye, there is still the problem that the drug cannot be adhered to a specific position

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug composite and application thereof
  • Drug composite and application thereof
  • Drug composite and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] The preparation of embodiment 1 injection and implant

[0057] Prescription 1-1 Sinomenine hydrochloride sodium hyaluronate injection (according to 100mL): 0.5g sinomenine hydrochloride, 2g sodium hyaluronate, 0.005g sodium dihydrogen phosphate dihydrate, 0.056 disodium hydrogen phosphate dodecahydrate g, sodium chloride 0.55g, EDTA 0.03g, sodium bisulfite 0.1g, and the balance is water for injection.

[0058] Prescription 1-2 Sinomenine hydrochloride sodium hyaluronate injection (according to 100mL): 1g sinomenine hydrochloride, 1.5g sodium hyaluronate, 0.005g sodium dihydrogen phosphate dihydrate, 0.065 disodium hydrogen phosphate dodecahydrate g, sodium chloride 0.5g, EDTA 0.03g, sodium bisulfite 0.2g, and the balance is water for injection.

[0059] Prescription 1-3 Sinomenine hydrochloride sodium hyaluronate injection (according to 100mL): 2.5g sinomenine hydrochloride, 1g sodium hyaluronate, 0.005g sodium dihydrogen phosphate dihydrate, 0.065 disodium hydrogen ph...

Embodiment 2

[0070] The preparation of embodiment 2 injection and implant

[0071]Prescription 2-1 Sinomenine hydrochloride cross-linked sodium hyaluronate gel (according to 100mL): 0.5g sinomenine hydrochloride, 2g cross-linked sodium hyaluronate, 0.005g sodium dihydrogen phosphate dihydrate, dodecahydrate phosphoric acid 0.06g of disodium hydrogen, 0.55g of sodium chloride, 0.03g of EDTA, 0.1g of sodium metabisulfite, and the balance is water for injection.

[0072] Prescription 2-2 Sinomenine hydrochloride cross-linked sodium hyaluronate gel (according to 100mL): 1g sinomenine hydrochloride, 1.5g cross-linked sodium hyaluronate, 0.005g sodium dihydrogen phosphate dihydrate, dodecahydrate phosphoric acid Disodium hydrogen 0.065g, sodium chloride 0.5g, EDTA 0.03g, sodium bisulfite 0.2g, and the balance is water for injection.

[0073] Prescription 2-3 Sinomenine hydrochloride cross-linked sodium hyaluronate gel (100mL): 1.5g sinomenine hydrochloride, 2g cross-linked sodium hyaluronate, 0...

Embodiment 3

[0089] The preparation of embodiment 3 external gel and propellant

[0090] Prescription 3-1 Sinomenine hydrochloride sodium hyaluronate gel (according to 100mL): 0.5g sinomenine hydrochloride, 1g sodium hyaluronate, 0.007g acetic acid, 0.04g sodium acetate, 3g glycerin, 0.03g EDTA, coke Sodium sulfite 0.1g, methylparaben 0.02g, propylparaben 0.01g, HPMC 2g, and the balance is purified water.

[0091] Prescription 3-2 Sinomenine hydrochloride sodium hyaluronate gel (according to 100mL): 1g sinomenine hydrochloride, 2g sodium hyaluronate, 0.03g EDTA, 0.2g sodium bisulfite, 0.03g ethyl paraben , carbomer 1.2g, triethanolamine 1g, polyethylene glycol 4005g, and the balance is purified water.

[0092] Prescription 3-3 Sinomenine hydrochloride sodium hyaluronate gel (according to 100mL): 2g sinomenine hydrochloride, 3g sodium hyaluronate, 0.08g boric acid, 0.45g sodium chloride, 0.05g EDTA, sodium bisulfite 0.2g, potassium sorbate 0.5g, and the balance is purified water.

[0093...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a drug composite, which is characterized in that the drug composite comprises the following components: a) one of isoquinoline composites and b) one or the mixture of two of hyaluronate or hyaluronic acid derivative. The composite of the invention can be used for preparing drug preparations which are taken in a non-oral may, is especially used for preparing the drug preparations for treating relevant diseases in the partial administration of articular cavity and posterior segment eye and has the characteristics of good treatment effect and less toxic and side effects.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to a pharmaceutical composition containing isoquinoline compounds and hyaluronic acid, and the use of the composition in preparing pharmaceutical preparations for non-oral administration. Background technique [0002] Isoquinoline alkaloids are widely distributed in the plant kingdom, mainly distributed in more than 10 species such as Fangjiceae, Ranunculaceae, Berberidaceae, Magnoliaceae, Papaveraceae, Anemoneaceae, Lauraceae, Rutaceae, Genusaceae, Nymphaeaceae, etc. in a plant group. Isoquinoline alkaloids can be divided into simple isoquinolines, benzyl isoquinolines, benzophenanthridines, naphthyl isoquinolines, aporphenites, proberberines, There are more than 20 kinds of tonics, morphine, etc., with a total of more than 1,000 kinds. Due to its diverse structures, it has various physiological activities such as anti-inflammation, anti-tumor, anti-bacterial, anti-abuse, analgesia, anti-ar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4725A61P27/02A61P19/02A61K31/485A61K31/4375A61K31/4741A61K31/4748A61K31/728
Inventor 凌沛学陈建英贺艳丽陈彬合刘杰汪敏荣晓花
Owner INST OF BIOPHARM OF SHANDONG PROVINCE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com